CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer

BiTE (bispecific T-cell engager) immune therapy has demonstrated clinical activity in multiple tumor indications, but its influence in the tumor microenvironment remains unclear. CLDN18.2 is overexpressed in solid tumors including gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC), both...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2023-11, Vol.165 (5), p.1219-1232
Hauptverfasser:	Xu, Yao, Fu, Juan, Henderson, MacKenzie, Lee, Fei, Jurcak, Noelle, Henn, Anja, Wahl, Joachim, Shao, Yingkuan, Wang, Jianxin, Lyman, Melissa, Funes, Vanessa, Espinoza, Birginia, Zhang, Rui, Washington, India, Chen, Sophia Y., Zlomke, Haley, Wang, Junke, Niu, Nan, Li, Pan, Meng, Fengxi, Burns, William, Friedrich, Matthias, Stienen, Sabine, Bailis, Julie M., Zheng, Lei
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Bispecific - genetics Antibodies, Bispecific - pharmacology Bispecific Antibody Carcinoma, Pancreatic Ductal - drug therapy Cell Adhesion Molecules Claudins Humans Immune Checkpoint Blockade Immunity Mice Pancreatic Neoplasms - drug therapy RNA Sequencing T-Lymphocytes, Regulatory - metabolism Tumor Microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!